SCHEMBL4676492

SCHEMBL4676492

O=C(Cc1occc1Cc1ccccn1)C(=O)c1nn[nH]n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.33
FFAR2 O15552 1/20 0.33
CXCR3 P49682 1/20 0.33
RAB9A P51151 2/20 0.33
ALDH1A1 P00352 1/20 0.33
NPC1 O15118 1/20 0.33
CES1 P23141 1/20 0.32
NCEH1 Q6PIU2 1/20 0.32
KDM4E B2RXH2 2/20 0.32
LMNA P02545 2/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678416 0.92 L3MBTL1 (0.33) L3MBTL1FFAR2CXCR3RAB9AALDH1A1
SCHEMBL4676202 0.84 CES1 (0.42) L3MBTL1ALDH1A1CES1NCEH1HDAC3
SCHEMBL4672194 0.84 L3MBTL1 (0.34) L3MBTL1RAB9AALDH1A1NPC1KDM4E
SCHEMBL4675770 0.83 TSHR (0.35) FFAR2CXCR3RAB9AALDH1A1NPC1
SCHEMBL4672920 0.83 RAB9A (0.36) FFAR2CXCR3RAB9ANPC1CES1
SCHEMBL4676479 0.82 RAB9A (0.35) FFAR2CXCR3RAB9ANPC1CES1
SCHEMBL4677550 0.82 MPO (0.34) L3MBTL1CXCR3RAB9AALDH1A1NPC1
SCHEMBL4673351 0.81 CYP17A1 (0.33) FFAR2RAB9ANPC1CES1NCEH1
SCHEMBL4677436 0.80 HDAC3 (0.34) FFAR2CXCR3RAB9ANPC1CES1
SCHEMBL4676131 0.79 SMN1; SMN2 (0.35) FFAR2CXCR3RAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 L3MBTL1 1170/4885FFAR2 2618/4885CXCR3 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.